Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Imaging, subjective complaints, and MCI: 30 years before

  • 83 Accesses

  • 4 Citations

Abstract

The neuropathological and cognitive changes preceding Alzheimer’s disease (AD) appear to begin decades before disease symptoms make the clinical diagnosis obvious. Clinical trials have begun to focus on preventive treatments aimed to slow cognitive decline in people with only subjective memory complaints. However, it is not clear how many years before clinical diagnosis of Alzheimer’s disease is possible to recognize early signs of neurodegeneration. We report evidence from the literature showing feasibility to diagnose AD at the stage of mild cognitive impairment (MCI) and also a few years before the MCI stage with imaging markers. However, we showed that neuroimaging brain changes evidenced decades before MCI are not early signs of neurodegeneration but expression of genetic risk states for AD or markers of inter-individual variability of cognitive performance due to genetic or environmental factors.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Smith AD. Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci U S A 2002;99: 4135–7.

  2. 2.

    Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68: 828–36.

  3. 3.

    Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32: 486–510.

  4. 4.

    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5: 228–34.

  5. 5.

    Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68: 1603–6.

  6. 6.

    Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007; [Epub ahead of print]

  7. 7.

    Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol 2006;5: 828–34.

  8. 8.

    Smith CD, Chebrolu H, Wekstein DR, et al. Brain structural alterations before mild cognitive impairment. Neurology 2007;68: 1268–73.

  9. 9.

    Mosconi L, De Santi S, Li J, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2007; [Epub ahead of print]

  10. 10.

    Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol 2006;59: 673–81.

  11. 11.

    de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001;98: 10966–71.

  12. 12.

    Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006;67: 834–42.

  13. 13.

    Wang PJ, Saykin AJ, Flashman LA, et al. Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging 2006;27: 1613–7.

  14. 14.

    Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging 2006;27: 1751–6.

  15. 15.

    van der Flier WM, van Buchem MA, Weverling-Rijnsburger AW, et al. Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. J Neurol 2004;251: 671–5.

  16. 16.

    Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology 1993;43: 515–9.

  17. 17.

    Bassett SS, Yousem DM, Cristinzio C, et al. Familial risk for Alzheimer’s disease alters fMRI activation patterns. Brain 2006;129: 1229–39.

  18. 18.

    Small GW. Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer’s disease. Adv Drug Deliv Rev 2002;54: 1561–6.

  19. 19.

    Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA. 2005;102: 8299–302.

  20. 20.

    Scarmeas N, Habeck CG, Stern Y, Anderson KE. APOE genotype and cerebral blood flow in healthy young individuals. JAMA 2003;290: 1581–2.

  21. 21.

    Filippini N, Scassellati C, Boccardi M, et al. Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. Eur J Hum Genet 2006;14: 443–9.

Download references

Author information

Correspondence to G. B. Frisoni.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Galluzzi, S., Frisoni, G.B. Imaging, subjective complaints, and MCI: 30 years before. J Nutr Health Aging 12, S80–S83 (2008). https://doi.org/10.1007/BF02982592

Download citation

Keywords

  • Mild Cognitive Impairment
  • Mild Cognitive Impairment Patient
  • Neurobiol Aging
  • Subjective Memory Complaint
  • Brain Volume Change